GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China
TOKYO--(BUSINESS WIRE)--GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced…